The role of cardiopulmonary exercise tests in pulmonary arterial hypertension

Stefania Farina1, Michele Correale2, Noemi Bruno1,3, Stefania Paolillo4, Elisabetta Salvioni1, Roberto Badagliacca5 and Piergiuseppe Agostoni1,6

on behalf of the “Right and Left Heart Failure Study Group” of the Italian Society of Cardiology

Affiliations: 1Centro Cardiologico Monzino, IRCCS, Milan, Italy. 2Dept of Cardiology, University of Foggia, Foggia, Italy. 3AOR S.Carlo, Dipartimento Cardiovascolare, Potenza, Italy. 4IRCCS SDN, Istituto di ricerca diagnostica e nucleare, Naples, Italy. 5Dipartimento di Scienze Cardiovascolari, Respiratorie, Nefrologiche, Anestesiologiche e Geriatriche, “La Sapienza” University of Rome, Rome, Italy. 6Dept of Clinical Sciences and Community Health (Cardiovascular Section), University of Milan, Milan, Italy.

Correspondence: Piergiuseppe Agostoni, Dept of Cardiovascular Sciences, Centro Cardiologico Monzino, IRCCS, via Parea 4, Milan 20138, Italy. E-mail: piergiuseppe.agostoni@ccfm.it

CPET provides valuable information on diagnosis, prognosis and therapy in PAH but it should be performed by experts

Cite this article as: Farina S, Correale M, Bruno N, et al. The role of cardiopulmonary exercise tests in pulmonary arterial hypertension. Eur Respir Rev 2018; 27: 170134 [https://doi.org/10.1183/16000617.0134-2017].

ABSTRACT Despite recent advances in the therapeutic management of patients affected by pulmonary arterial hypertension (PAH), survival remains poor. Prompt identification of the disease, especially in subjects at increased risk of developing PAH, and prognostic stratification of patients are a necessary target of clinical practice but remain challenging. Cardiopulmonary exercise test (CPET) parameters, particularly peak oxygen uptake, end-tidal carbon dioxide tension and the minute ventilation/carbon dioxide production relationship, emerged as new prognostic tools for PAH patients. Moreover, CPET provides a comprehensive pathophysiological evaluation of patients’ exercise limitation and dyspnoea, which are the main and early symptoms of the disease. This review focuses on the role of CPET in the management of PAH patients, reporting guideline recommendations for CPET and discussing the pathophysiology of exercise limitation and the most recent use of CPET in the diagnosis, prognosis and therapeutic targeting of PAH.

Introduction

The cardiopulmonary exercise test (CPET) is a noninvasive method to assess functional capacity and exercise limitation, providing information about the cardiovascular, respiratory, metabolic and muscular response to physical effort. It can be recommended for all patients suffering from pulmonary hypertension (PH) who are able to perform exercise testing and are clinically stable (New York Heart Association (NYHA) functional groups I–III). Indeed, CPET is a safe test even in patients with severe exercise limitation. As noted, it is a noninvasive method and is usually performed without assessment of arterial blood gases. However, a differential diagnosis between group 1 (pulmonary arterial hypertension (PAH)) and group 3 (PH due to lung disease) might require an evaluation of changes in arterial carbon dioxide tension (Paco2) during exercise and in cardiac output (CO)/oxygen uptake (VO2) ratio [1]. Nowadays, CPET parameters, particularly peak VO2, end-tidal carbon dioxide tension (PETCO2) and the minute
ventilation ($V′e$)/carbon dioxide production ($V′CO₂$) relationship (measured either as its ratio at the anaerobic threshold (AT) or as its relationship slope) are considered to be of the utmost importance in the diagnosis, prognosis and therapeutic management of PAH patients. However, all CPET-derived parameters are underused even in major PH centres. This is likely due to a lack of expertise in the carrying out of CPET and because, besides haemodynamic measurements, the functional class (which is based on symptoms during exercise) and the six-minute walk test (6MWT) were historically considered enough to stratify PAH risk and predict patients’ prognosis.

In this review we address the strengths and limitations of the use of CPET in PAH, focusing on pioneering use, current and previous guidelines, physiological background and CPET use in PAH diagnosis and prognosis.

The CPET in PAH: from experience to guidelines

PH is a progressive disease that leads to increased pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) as well as to loss of pulmonary vasodilator response to exercise. The main and early symptoms in PH are exercise intolerance and dyspnoea.

The clinical interest in PH is relatively recent and has developed in the last 40 years, starting after a sudden increase in PH diagnosis in Switzerland, Germany and Austria in 1967 linked to the intake of appetite-reducing drugs. The First World Symposium on Pulmonary Hypertension [2], which took place in Switzerland in 1973, proposed the first definition of primary pulmonary hypertension (PPH; PH of unknown cause) and secondary PH (PH of known cause), focusing basically on the epidemiologic and pathophysiological features of the disease since no specific therapy was available. In the 1990s, epoprostenol was the first PH-specific drug that was demonstrated to prolong survival and improve functional capacity, assessed as distance walked, in PPH patients [3, 4]. Therefore, starting from World Symposium on Primary Pulmonary Hypertension in Evian (1998) and carrying on during the world symposia on PH held in Venice (2003), Dana Point (2009) and Nice (2013), the guidelines were revised and the PH classification system improved, identifying four different categories sharing similarities in pathophysiological mechanisms, clinical presentation and therapeutic options. Indeed, a few specific therapies were approved simultaneously in the 2000s for the first group of the classification system, namely PAH [5–8].

The first trials mainly included patients with severe PAH and they demonstrated that haemodynamic data, functional class and the 6MWT were able to predict mortality and response to treatment [9–11]. For these reasons and thanks to the simplicity of execution for both patients and physicians, the 6MWT has been and remains until now the only exercise endpoint accepted by the Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products for studies evaluating treatment effects in PAH, even if it has been demonstrated that the change in distance walked does not correlate with survival or clinical events such as hospitalisations or need for rescue therapy [12]. Results from the STRIDE-I trial, the first and only trial that used both 6MWT and CPET as endpoints, were also against the use of CPET-derived parameters for PAH evaluation [13]. Indeed, the study drug, sitaxentan, significantly improved the 6MWT distance but not peak $V′O₂$ [13]. Moreover, the 6MWT and CPET parameters were not correlated, with the lack of sufficient expertise and accepted standardisation methods in performing exercise tests in PH patients being suggested as the main reasons for this unexpected discrepancy [14]. Indeed, OUDIZ et al. [14] showed that the correlation between the 6MWT and CPET measurements improved significantly as the study progressed, as did technical skills at less-experienced sites (where ability increased over time). A further important reason for discrepancy in the STRIDE study lies in considering the 6MWT unadjusted for body weight. Indeed, by taking into account patients’ body size, OUDIZ et al. [14] were able to show an increased correlation between 6MWT and CPET.

All these observations confirm the need for quality-controlled CPET, as reported in guidelines starting from 2009 [7]. However, in contrast to 6MWT that provides only limited clinical information, CPET has the power to reveal the underlying pathophysiological consequences of the disease process and, in recent years, several CPET variables have been recognised to be consistently altered in patients with PAH [15, 16]. Thus, 6MWT should be considered as complementary to CPET and not a replacement for it according to the American Thoracic Society (ATS) [17]. Specifically, WENSEL et al. [18] found, in 70 patients affected by idiopathic PAH, that systolic blood pressure at peak exercise, peak $V′O₂$, exercise duration, $PETCO₂$ at rest, $V′e/V′CO₂$ slope, diastolic blood pressure at peak exercise and heart rate (HR) at peak exercise predicted survival. Moreover, on multivariate analysis, peak $V′O₂$ and systolic blood pressure were independent predictors of survival, while haemodynamic parameters were not independently predictive of mortality.

Starting from these data, the Dana Point guidelines reported the use of peak $V′O₂$ as a prognostic tool in the follow-up of PAH patients, particularly younger patients who are likely able to walk more than 500 m
despite the presence of severe PAH and right ventricular (RV) dysfunction [7]. In these patients, 6MWT is expected to be a submaximal test and, therefore, the additional exercise testing with CPET is particularly useful in order to obtain a more reliable assessment of functional status and RV function. In the most recent guidelines [19], a typical ventilatory pattern with low PetCO2 and high V′E/V′CO2 is also highlighted and V′E/V′CO2 slope is included in the risk assessment of PAH patients with cut-off values based on expert opinion (table 1).

### Physiology of exercise in PAH

The origin of exercise intolerance and the occurrence of dyspnoea in PAH patients may be attributable to several pathophysiological mechanisms [20]. First, during exercise, CO should rise to meet the increased demand for oxygen by peripheral muscles. However, in patients with pulmonary vascular disease, CO fails to increase during exercise due to a further rise in mean pulmonary arterial pressure (mPAP) and RV failure, with consequent inadequate tissue oxygen delivery and thus the generation of early lactic acidosis [15, 21, 22]. In a recent pilot study on invasive exercise haemodynamics, LADOR et al. [23] reported the CO kinetics at the onset of exercise in PAH patients. The cardiac adaptation to exercise appeared to be slower in PAH patients than in controls, with a decrease in CO at the onset of exercise due to a transitory decrease in stroke volume, probably related to increased venous return and consequent worsening RV function. Moreover, during effort, no significant increase in stroke volume was observed, indicating that the increase in CO during exercise was attributable to the increase in HR. In the setting of CO assessment in PH, both pre-capillary and post-capillary, FARINA et al. [24] reported an overall agreement among CO determination by thermodilution, the direct Fick method and the inert gas rebreathing technique (Innocor Rebreathing System, Innovision A/S, Odense, Denmark) in patients with PH without significant arterial hypoxaemia, suggesting the possibility of a noninvasive and better-tolerated haemodynamic follow-up in these patients. Unfortunately, reliable data on noninvasive assessment of exercise CO are presently lacking.

Secondly, abnormalities in arterial blood gases also play a role in exercise intolerance. In PAH, mild-to-moderate arterial hypoxaemia and arterial hypocapnia are due to a combination of low mixed venous oxygen saturation, high physiologic dead space, low alveolar–arterial diffusion and right-to-left shunt through either a patent foramen ovale or intrapulmonary shunt. Hypoxaemia exacerbates the early occurrence of lactic acidosis and stimulates the carotid bodies to augment the ventilatory drive, contributing to an excessive increase in V′E during exercise [25]. In any case, the increased ventilatory response to physical activity is associated with a reduced perfusion of well-ventilated alveoli. This ventilation–perfusion mismatch causes high physiologic dead space (Vd) to tidal volume (VT) ratio, or inefficient ventilation, reflected in a high V′E/V′CO2 ratio measurable both as V′E/V′CO2 at a given exercise level or as the slope of the V′E/V′CO2 relationship [26]. The two possible behaviours of the V′E/V′CO2 relationship are reported in figure 1. In figure 1a, hyperventilation did not influence the physiologic domains of V′E during exercise and these are thus maintained such that the characteristic slopes of the V′E versus V′CO2 relationship can be appreciated. In figure 1b, the ventilatory stimuli are so strong as to overwhelm normal physiology, such that a single slope characterises the V′E/V′CO2 relationship. The increase in V′E/V′CO2 slope is paralleled by an increase in dead space ventilation during exercise. This is approximately one third of V′E, a value much higher when compared to healthy subjects, in whom dead space V′E physiologically declines during exercise [27, 28]. The increase of functional Vd/VT and of ventilation also leads to a reduction of PetCO2 at rest and to a further decrease during exercise. Low PetCO2 is related to ventilatory inefficiency, which causes the dilution of PetCO2 relative to PacO2. Furthermore, PetCO2 reduction is proportional to peak V′CO2 impairment and inversely correlated with the elevation in mPAP [29]. The arterial to end-tidal carbon dioxide tension difference (Pa-ETCO2), a reflection of ventilation–perfusion inequality, is positive at rest and increases in patients with PAH, whereas, in healthy people, Pa-ETCO2 is reduced and often negative at peak exercise [30]. Another feature is the dynamic hyperinflation observed in 60% of PH patients studied by LAVENEZIANA et al. [31]. This paper is

### TABLE 1 Cardiopulmonary exercise test (CPET) determinants of prognosis in risk assessment

| CPET parameters | Low Risk (<5%) | Intermediate risk (5–10%) | High risk (>10%) |
|-----------------|----------------|---------------------------|-----------------|
| Peak V'O2 ml·kg⁻¹·min⁻¹ | >15            | 11–15                     | <11             |
| Peak V'O2 % predicted | >65            | 65–35                     | <35             |
| V'E/V'CO2 slope | <36            | 36–45                     | >45             |

V'O2: oxygen uptake; V'E: minute ventilation; V'CO2: carbon dioxide production; V'E/V'CO2 slope: slope of the relationship between V'E and V'CO2.
interesting not only because of the Pa-ETCO2 concept but also because of the respiratory mechanic abnormalities assessment by inspiratory capacity manoeuvres. In this respect, the visual inspection of the $V_E'/V'_CO2$ relationship gives a lot of information (figure 2). Indeed, the slope is high and the $V_E'$-axis intercept (i.e. when $V'_CO2=0$) is often close to zero or negative. This means that dead space $V_E'$ increases progressively during exercise. Notably, when two linear segments are identified on the $V_E'/V'_CO2$ relationship plot, the second has a very high slope and a severely negative $V_E'$-axis intercept, showing that the increase of dead space $V_E'$ pertains specifically to the last part of exercise.

**FIGURE 1** The minute ventilation ($V_E$)/carbon dioxide production ($V'_CO2$) relationship slope in two pulmonary arterial hypertension patients. In (a) the physiological behaviour of ventilation during exercise is preserved in spite of hyperventilation, such that two slopes can be recognised around the respiratory compensation (RC) point (slope 1 ($S1$)=40.4 and slope 2 ($S2$)=55.1). In (b) a single slope characterises the $V_E'/V'_CO2$ relationship.

**FIGURE 2** The minute ventilation ($V_E$)/carbon dioxide production ($V'_CO2$) relationship slope in a patient with pulmonary arterial hypertension and preserved physiological behaviour of the $V_E'/V'_CO2$ relationship during exercise. In the first part of exercise, the $V_E'/V'_CO2$ slope is high and the $V_E'$-axis intercept is close to zero. This means that dead space ventilation progressively increases during exercise. After the end of isocapnic buffering, i.e. at the respiratory compensation (RC) point, the slope becomes steeper and the $V_E'$-axis intercept becomes severely negative showing that dead space ventilation severely increases toward the end of exercise. Reproduced from [32] with permission.
Thirdly, an increase in chemosensitivity could also play a role in PAH hyperventilation. Indeed, severe PAH leads to RV failure and consequently to low CO, which could activate a sympathetic response similar to that described in left-ventricular failure. Additionally, the further augmentation of catecholamines, arterial potassium level elevation, progressive lacticidemia, enhanced RV distension, higher pulmonary intra-vascular pressures, hypoxaemia and increased oscillations in pH may also contribute to increased chemoreflex activity during exercise [33]. Indeed, only very recently Farina et al. [28] demonstrated an increase in chemosensitivity for oxygen and carbon dioxide. Specifically, the central carbon dioxide chemoreceptor presented a direct correlation with alveolar V′E, suggesting a preserved role for central chemoreceptor activity and alveolar V′E increase during exercise. Notably, functional hypercapnic chemosensitivity is predominantly mediated by the central chemoreceptors, while peripheral hypercapnic chemosensitivity accounts for only one tenth of the overall carbon dioxide chemosensitivity [34]. However, the mechanisms which cause altered chemosensitivity are unclear. Indeed, besides the traditionally recognised stimuli such as low partial pressure of oxygen (P[O2]), high partial pressure of carbon dioxide (P[CO2]) and unbuffered acidosis, a direct role for lactic acid on peripheral chemoreflex activity and chemoreflex stimulation has been suggested [35, 36].

Finally, respiratory and peripheral muscle impairment and fatigue could also contribute to exercise intolerance. Peripheral muscle dysfunction in PAH is related to low CO, vasoconstriction and deconditioning, but it may also be due to altered skeletal muscle microcirculation [37]. Laveneziana et al. [31] showed that PAH patients have preserved inspiratory muscle function regardless of changes in dynamic inspiratory capacity during cycle exercise and that the inspiratory capacity manoeuvre is reliable in evaluating dynamic hyperinflation during CPET in PAH. Metabo-reflexes likely contribute to exercise-induced hyperventilation in PAH, as is the case in patients with left-heart failure [38]; however, this has only very recently been shown in PAH [24].

The use of the CPET in the diagnosis of PAH
CPET is useful to support the diagnosis of PAH both in patients with dyspnoea of unknown aetiolo and in patients with symptoms, signs, history and echocardiographic findings suggestive of PH, allowing the identification of typical cardiac and ventilatory patterns during exercise. Moreover, in the diagnostic process, CPET is suitable for establishing and guiding therapeutic management [19, 39] and it has recently been demonstrated to be predictive of haemodynamic findings [40]. The CPET parameters associated with PAH are reported in table 2.

| Reduced parameters       | Increased parameters                                      |
|--------------------------|----------------------------------------------------------|
| Peak V′O2                | V′D/V′T during exercise (>30%)                            |
| WR                       | P[Ar]-P[O2] differences during exercise                  |
| O2 pulse                 | (up to 45 mmHg or over)                                  |
| V′O2/WR                  | P[ETCO2] at rest                                        |
| P[ETCO2] at AT           | P[ETCO2] at AT                                          |
| O2 saturation during exercise | drop >3% without P[CO2] rise                            |

V′O2: oxygen uptake; V′D: dead space volume; V′T: tidal volume; WR: work rate; P[Ar]-P[O2]: alveolar−arterial oxygen tension difference; P[ETCO2]: end-tidal carbon dioxide tension; AT: anaerobic threshold; P[CO2]: arterial carbon dioxide tension.
The presence of pulmonary vascular limitation and is associated with an increase in alveolar–venous oxygen difference (due to hypoxia-related low arterial oxygen content) also plays a major role. However, inert gas studies suggest that hypoxaemia during exercise in PAH is explained by low mixed venous oxygen and high mean $\dot{V}CO_2$ even without impaired gas diffusion [43].

Peak $\dot{V}O_2$ describes the presence of a functional impairment and its absolute or percent predicted value is used to grade the severity of exercise limitation in patients affected by cardiac diseases. Peak $\dot{V}O_2$ correlates well with NYHA class in PAH patients. The kinetics of $\dot{V}O_2$ increase during unloaded cycling exercise are impaired in this population, as demonstrated by an increase in mean response time (MRT), indicating a less efficient coupling of oxygen delivery and uptake [20].

At exercise are necessary to calculate $Vd/Vt$ [42]. $Vd/Vt$ increase of >30% during exercise indicates the presence of pulmonary vascular limitation and is associated with an increase in alveolar–arterial gradient (to 45 mmHg or more) caused by $V\dot{E}$/perfusion mismatch and by low alveolar–capillary gas diffusion. In a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH. Indeed, besides a low stroke volume, a low arterial $\dot{V}O_2$ pulse, and a different fashion to heart failure there are multiple causes of oxygen pulse reduction in PAH.
retrospectively. Compared to non-PAH patients, PAH subjects showed lower peak \( V'O_2 \) and anticipated AT, higher \( Ve/V'CO_2 \) slope and lower \( PETCO_2 \) values. Moreover, they found that the combination of \( Ve/V'CO_2 \) slope and AT led to a specificity of 95% and a sensitivity of 92.6% for the identification of PAH.

In addition to these parameters, PAH patients usually experience a decrease in oxygen saturation from rest to peak exercise of >3% without a rise in \( PaCO_2 \), which has been recognised for many years as a major criterion of pulmonary vascular exercise limitation [45]. This behaviour is commonly found in subjects with moderate, severe and very severe impaired PAH, and this reduction is proportional to the severity of the disease. The presence of desaturation is also related to the opening of a right-to-left exercise-induced shunt. PAH patients with shunt show the lowest values of \( PETCO_2 \) at rest. In this regard, it is of note that when an abrupt decrease of \( PETCO_2 \) and an abrupt increase of end-tidal oxygen tension (\( PETO_2 \)), \( Ve/V'O_2 \) and respiratory exchange ratio are observed during exercise, followed by a reduction in oxygen saturation, the beginning of a right-to-left shunt possibly due to the opening of a patent foramen ovale must be suspected [46].

Regarding emerging CPET variables, PAH patients exhibit low values of the oxygen uptake efficiency (OUE) plateau (calculated as the 90 s average of the highest consecutive measurements of \( V'O_2/V'\text{E} \) near AT) and the OUE slope (calculated as the regression slope “\( a \)” in \( V'O_2=ax\log_{10}(V'\text{E}+b) \), indicating ventilatory inefficiency during exercise [47] (figure 3). TAN et al. [48] compared 32 patients with idiopathic PAH to 16 controls and showed that OUE slope and OUE plateau were significantly lower and the \( Ve/V'CO_2 \) slope was significantly higher in the former. Similarly, the study by ZHAO et al. [44] mentioned above showed a reduction of OUE slope and OUE plateau in patients with a suspicion of PH that accompanies the already mentioned typical CPET pattern observed in this population. These parameters are promising variables in the diagnostic management of PAH patients; however, more data are needed to confirm these initial findings.

The use of the CPET for prognostication in PAH
Right-heart catheterisation remains the gold standard to confirm a diagnosis of PAH. Some CPET parameters can predict or sometimes confirm the vascular disease pattern but they cannot confirm a diagnosis of PAH. In fact, CPET sometimes provides an indication for right-heart catheterisation. However, CPET can provide important prognostic information regarding patients with pulmonary diseases [26]. Exercise variables, such as peak \( V'O_2, Ve/V'CO_2 \) and arterial oxygen saturation (\( SaO_2 \)) are able to better predict prognosis than resting lung function measurements. A number of CPET variables have been shown to be consistently altered in patients with PAH and they play a role in prognostic stratification in both PAH and chronic thromboembolic pulmonary hypertension (CTEPH) [49]. However, although most of these variables provide prognostic information, peak \( V'O_2 \) is most widely used for therapeutic decision making [18, 41, 50, 51].

![Figure 3](https://doi.org/10.1183/16000617.0134-2017)
It should be noticed that, although treatment advances in the last two decades have improved symptoms and survival of patients with PAH, prognosis remains poor and individual risk stratification is still of major importance. Therefore, it is mandatory to establish the appropriate treatment strategy and a mild approach with oral drugs or a more aggressive approach including parenteral prostanooids are both considered in international guidelines based on risk assessment [19]. However, how to translate into clinical practice the multiparametric approach to risk stratification proposed by current guidelines is still unclear. Further studies on PAH are needed to allow for a more comprehensive, definite and documented integration of CPET into the guidelines list of “variables to consider for severity assessment”, which, at present, only mentions expert opinion values for peak \( V'O_2 \) and \( V'E/V'CO_2 \) [19]. Indeed, more robust prognostic evidence for peak \( V'O_2 \) and \( V'E/V'CO_2 \) arises from the studies by WENSEL et al. [50] and DEBESCK et al. [52], both powered for multivariate analysis in a modern treatment context, although the added value of CPET on top of common clinical and haemodynamic variables remains unexplored. Recently, however, BADAGLICACC et al. [53] documented the increased power of a risk prediction model considering oxygen pulse and echocardiographically-determined RV systolic function compared to the traditional model including clinical, invasive haemodynamic and 6MWT variables. Indeed, a combination of low RV fractional area change and low oxygen pulse might identify patients at a particularly high risk of clinical deterioration.

The 6MWT is the most used test to predict survival in PAH patients and, in order to assess whether CPET adds prognostic value to the information derived from 6MWT, it has been demonstrated that CPET parameters predict survival in PAH patients and add information to the prognostic value of 6MWT [54]. For example, after multivariable Cox regression, reduction in \( SaO_2 \) during exercise significantly improved the univariate 6MWT prediction model. SCHNABLMAIR et al. [49] determined ventilatory efficiency in PAH and chronic thromboembolic PAH patients through CPET, identifying PAH patients with increased risk of death within 24 months from evaluation. The authors showed significant differences between survivors and non-survivors in ventilatory equivalents for oxygen (42.1±2.1 \( \text{versus} \) 56.9±2.6; \( p<0.005 \)) and for carbon dioxide (47.5±2.2 \( \text{versus} \) 64.4±2.3; \( p<0.005 \)). Patients with peak oxygen uptake \( \leq 10.4\ \text{mL\cdotmin}^{-1}\cdot\text{kg}^{-1} \) had a 1.5-fold higher risk of mortality in the following 24 months. The risk was 7.8-fold higher with a \( V'E/V'CO_2 \) ratio at AT \( \geq 55 \), 2.9-fold higher with an alveolar--arterial oxygen difference \( \geq 55 \text{mmHg} \) and 5.8-fold higher with a \( V'E/V'CO_2 \) slope \( \geq 60 \).

There are different considerations about the prognostic role of CPET in the treatment of PAH. GROEPENHOFF et al. [55] showed that survivors had a significantly greater change in peak \( V'O_2 \) than nonsurvivors and this change in aerobic capacity was significantly related to changes in right ventricular ejection fraction (RVEF). Notably, treatment-associated changes in \( V'O_2 \) and oxygen pulse predicted survival, whereas changes in \( V'E/V'CO_2 \) slope did not.

In addition, the combined use of peak \( V'O_2 \) and PVR provides accurate risk stratification underlining the important and complementary prognostic information from cardiopulmonary exercise testing and resting invasive haemodynamic data [50]. These different approaches may be complementary in the risk stratification of PAH patients and exercise haemodynamic data has been correlated with peak \( V'O_2 \) [56] to determine their prognostic significance. This has shown that exercise cardiac index correlates with peak \( V'O_2 \) and is the only independent predictor of peak \( V'O_2 \) on multivariate stepwise linear regression analyses. Furthermore, peak \( V'O_2 \) is the strongest predictor of survival in this analysis.

FERRIE et al. [57] have demonstrated that, considering all data points, measurements of excessive exercise \( V'E \) might improve the usefulness of incremental CPET in the prognostic evaluation of PAH. OUE slope may also be a useful noninvasive marker of disease severity and outcome in paediatric patients [58]. Indeed, it has been demonstrated that ventilatory efficiency slope in children and young adults with a diagnosis of PAH and poor outcomes (nine deaths, three lung transplants) is significantly elevated compared to patients with better outcomes (51.1 \( \text{versus} \) 37.9; \( p<0.001 \)). Moreover, the persistence or development of an exercise-induced right-to-left shunt strongly predicts death or transplantation in PAH patients, irrespectively of the haemodynamics and all other exercise measures including peak \( V'O_2 \) and OUE slope. Furthermore, a poorer OUE slope appears to be associated with a poor outcome in patients without a shunt. So, a persistent exercise-induced right-to-left shunt and poor ventilatory efficiency are highly predictive of poor outcomes in patients with PAH [59].

Another possible prognostic CPET-derived variable is the delayed post-exercise HR recovery (1 min) response [60], which is reportedly much lower in PH patients than in controls. The best cut-off for HR recovery in 1 min to discriminate between patients and controls is 18 beats. Patients with HR recovery (1 min) \( >18 \) had better NYHA scores, resting haemodynamics and 6MWT distance. On a multiple regression analysis that only considered CPET-independent variables, HR recovery (1 min) \( \leq 18 \) was the only predictor of mortality [60].
Conclusions

Today CPET is utilised for PH evaluation in only a few centres with expertise in the technique and there are currently very few data on the prognostic importance of treatment-induced changes in CPET variables. These preliminary results need to be confirmed in larger cohorts of patients and in a properly powered multicentric study. Furthermore, only an extensive use of CPET can confirm its role in the clinical assessment of PAH and provide a cost/effectiveness evaluation. The utility of CPET data from centres that seldom perform the technique or that are not specialised in the evaluation of PAH cases remains controversial.

Conflict of interest: P. Agostoni reports personal fees from Menarini, Novartis and Boeringer, and grants from Daiichi Sankyo, outside the submitted work.

References

1. Seeger W, Adir Y, Barbera JA, et al. Pulmonary hypertension in chronic lung diseases. *J Am Coll Cardiol* 2013; 62: D109–D116.
2. Hatano S, Strasser T, eds. Primary pulmonary hypertension: report on a WHO meeting. Geneva, World Health Organization, 1975. [http://apps.who.int/iris/bitstream/handle/10665/39094/9241560444_eng.pdf?sequence=1](http://apps.who.int/iris/bitstream/handle/10665/39094/9241560444_eng.pdf?sequence=1)
3. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. *N Engl J Med* 1996; 334: 296–301.
4. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. *Ann Intern Med* 1990; 112: 485–491.
5. Rich S, ed. Executive summary from the World Symposium on Primary Pulmonary Hypertension, 1998, World Symposium on Primary Pulmonary Hypertension, 1998, September 6–10, 1998, Evian, France, cosponsored by the World Health Organization.
6. Simonneau G, Galie N, Rubin L, et al. Clinical classification of pulmonary hypertension. *J Am Coll Cardiol* 2004; 43: 55–125.
7. Galie N, Hoepner MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J* 2009; 30: 2493–2537.
8. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Respir J* 2015; 46: 903–975.
9. Sibon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. *J Am Coll Cardiol* 2002; 40: 780–788.
10. Miyamoto S, Nagaya N, Sato T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. *Am J Respir Crit Care Med* 2000; 161: 487–492.
11. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). *Circulation* 2010; 122: 164–172.
12. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. *J Am Coll Cardiol* 2012; 60: 1192–1201.
13. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2004; 169: 441–447.
14. Oudiz RJ, Barst RJ, Hansen JE, et al. Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. *Am J Cardiol* 2006; 97: 123–126.
15. Weatherald J, Farina S, Bruno N, et al. Cardiopulmonary exercise testing in pulmonary hypertension. *Ann Am Thorac Soc* 2017; 14: S84–S92.
16. Paolillo S, Farina S, Bussetti M, et al. Exercise testing in the clinical management of patients affected by pulmonary arterial hypertension. *Eur J Prev Cardiol* 2012; 19: 960–971.
17. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med* 2002; 166: 111–117.
18. Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. *Circulation* 2002; 106: 319–324.
19. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J* 2016; 37: 67–119.
20. Sun XG, Hansen JE, Oudiz RJ, et al. Exercise pathophysiology in patients with primary pulmonary hypertension. *Circulation* 2001; 104: 429–435.
21. Groepenhoff H, Westerhof N, Jacobs W, et al. Exercise stroke volume and heart rate response differ in right and left heart failure. *Eur J Heart Fail* 2010; 12: 716–720.
22. Holverda S, Gan CT, Marcus JT, et al. Impaired stroke volume response to exercise in pulmonary arterial hypertension. *J Am Coll Cardiol* 2006; 47: 1732–1733.
23. Lador F, Bringard A, Bengueddache S, et al. Kinetics of cardiac output at the onset of exercise in precapillary pulmonary hypertension. *Biomed Res Int* 2016; 2016: 6050193.
24. Farina S, Teruzzi G, Cattadori G, et al. Noninvasive cardiac output measurement by inert gas rebreathing in suspected pulmonary hypertension. *Am J Cardiol* 2014; 113: 546–551.
25. Wasserman K, Hansen JE, Sue DY, et al. Principles of exercise testing and interpretation. 3rd Edn. Baltimore, Lippincott, Williams & Wilkins, 1999.
26. Ferrazza AM, Martolino D, Valli G, et al. Cardiopulmonary exercise testing in the functional and prognostic evaluation of patients with pulmonary diseases. *Respiration* 2009; 77: 3–17.
27. Robertson HT. Dead space: the physiology of wasted ventilation. *Eur Respir J* 2015; 45: 1704–1716.
Farina S, Bruno N, Agalbato C, et al. Physiological insights of exercise hyperventilation in arterial and chronic thromboembolic pulmonary hypertension. *Int J Cardiol* 2018; 259: 178–182.

Yasunobu Y, Oudiz RJ, Sun XG, et al. End-tidal *P*co2 abnormality and exercise limitation in patients with primary pulmonary hypertension. *Chest* 2005; 127: 1637–1646.

Jones NL, Robertson DG, Kane JW. Difference between end-tidal and arterial *P*co2 in exercise. *J Appl Physiol* 1979; 47: 954–960.

Laveneziana P, Garcia G, Joureau B, et al. Dynamic respiratory mechanics and exertional dyspnea in pulmonary arterial hypertension. *Eur Respir J* 2013; 41: 578–587.

Agostoni P, Farina S, Apostolo A, et al. Inside ventilatory regulation in pulmonary hypertension: several hidden data are still undiscovered. *Eur J Prev Cardiol* 2014; 21: 268–271.

Velez-Roa S, Ciarka A, Najem B, et al. Increased sympathetic nerve activity in pulmonary artery hypertension. *Circulation* 2004; 110: 1308–1312.

Dempsey JA, Smith CA. Pathophysiology of human ventilatory control. *Eur Respir J* 2014; 44: 495–512.

Parati G, Lombardi C, Castagna F, et al. Heart failure and sleep disorders. *Nat Rev Cardiol* 2016; 13: 389–403.

Chang AI, Ortega FE, Riegler J, et al. Oxygen regulation of breathing through an olfactory receptor activated by lactate. *Nature* 2015; 527: 240–244.

Potus F, Malenfant S, Graydon C, et al. Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2014; 190: 318–328.

Poniakowski PP, Chua TP, Francis DP, et al. Muscle ergoreceptor overactivity reflects deterioration in clinical status and cardiorespiratory reflex control in chronic heart failure. *Circulation* 2001; 104: 2324–2330.

McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. *Circulation* 2009; 119: 2250–2294.

Correale M, Tricario L, Ferraretti A, et al. Cardiopulmonary exercise test predicts right heart catheterization. *Eur J Clin Invest* 2017; 47: e12851.

Arena R, Lavie CJ, Milani RV, et al. Incremental prognostic value of cardiopulmonary exercise testing in patients with primary pulmonary arterial hypertension: an evidence-based review. *J Heart Lung Transplant* 2010; 29: 159–173.

Guazzi M, Marenzi G, Assanelli E, et al. Evaluation of the dead space/tidal volume ratio in patients with chronic congestive heart failure. *J Card Fail* 1995; 1: 401–408.

Dantzker DR, D’Alonzo GE, Bower JS, et al. Pulmonary gas exchange during exercise in patients with chronic obstructive pulmonary hypertension. *Am Rev Respir Dis* 1984; 130: 412–416.

Zhao QH, Wang L, Pudasaini B, et al. Cardiopulmonary exercise testing improves diagnostic specificity in patients with echocardiography-suspected pulmonary hypertension. *Clin Cardiol* 2017; 40: 95–101.

Agostoni P, Butler J. Cardiac evaluation. In: Murray JFE, Nadel JA, eds. *Textbook of respiratory medicine*. Boston, Saunders Company, 1994; pp. 943–962.

Sun XG, Hansen JE, Oudiz RJ, et al. Gas exchange detection of exercise-induced right-to-left shunt in patients with primary pulmonary hypertension. *Circulation* 2002; 105: 54–60.

Sun XG, Hansen JE, Stringer NW. Oxygen uptake efficiency plateau: physiology and reference values. *Eur J Appl Physiol* 2012; 112: 919–928.

Tan X, Yang W, Guo J, et al. Usefulness of decrease in oxygen uptake efficiency to identify gas exchange abnormality in patients with idiopathic pulmonary arterial hypertension. *PloS One* 2014; 9: e98889.

Schwaiblmair M, Faul C, von Scheidt W, et al. Ventilatory efficiency testing as prognostic value in patients with pulmonary hypertension. *BMC Pulm Med* 2012; 12: 23.

Wensel R, Francis DP, Meyer FJ, et al. Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. *Int J Cardiol* 2013; 167: 1193–1198.

Diller GP, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implications. *Circulation* 2005; 112: 828–835.

Deboeck G, Scoditti C, Huez S, et al. Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension. *Eur Respir J* 2012; 40: 1410–1419.

Badagliacca R, Papa S, Valli G, et al. Echocardiography combined with cardiopulmonary exercise testing for the prediction of outcome in idiopathic pulmonary arterial hypertension. *Clin Chest Med* 2016; 150: 1313–1322.

Groenenhoff H, Vonk-Noordegraaf A, Boonstra A, et al. Exercise testing to estimate survival in pulmonary hypertension. *Med Sci Sports Exerc* 2008; 40: 1725–1732.

Groenenhoff H, Vonk-Noordegraaf A, van de Veerendonk MC, et al. Prognostic relevance of changes in exercise test variables in pulmonary arterial hypertension. *PloS One* 2013; 8: e72013.

Blumberg FC, Arzt M, Lange T, et al. Impact of right ventricular reserve on exercise capacity and survival in patients with pulmonary hypertension. *Eur J Heart Fail* 2013; 15: 771–775.

Ferreira EV, Ota-Arakaki JS, Ramos RP, et al. Optimizing the evaluation of exercise ventilation for prognosis assessment in pulmonary arterial hypertension. *Eur J Prev Cardiol* 2014; 21: 1409–1419.

Rausch CM, Taylor AL, Ross H, et al. Ventilatory efficiency slope correlates with functional capacity, outcomes, and disease severity in pediatric patients with pulmonary hypertension. *Int J Cardiol* 2013; 169: 445–448.

Oudiz RJ, Midde R, Hovenesian A, et al. Usefulness of right-to-left shunting and poor exercise gas exchange for predicting prognosis in patients with pulmonary arterial hypertension. *Am J Cardiol* 2010; 105: 1186–1191.

Ramos RP, Arakaki JS, Barbosa P, et al. Heart rate recovery in pulmonary arterial hypertension: relationship with exercise capacity and prognosis. *Am Heart J* 2012; 163: 580–588.